How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,492 results for

NIH Stroke Scale

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score. (PubMed)

, Switzerland, as well as Frankfurt a.M., Germany. The score components were copeptin levels, age, NIH Stroke Scale, and recanalization therapy (CoRisk score). Copeptin levels were measured in plasma drawn within 24 hours of AIS and before any recanalization therapy. The primary outcome of disability and death at 3 months was defined as modified Rankin Scale score of 3 to 6.Overall, 1,102 patients were included in the analysis; the derivation cohort contributed 319 patients, and the validation cohort (...) A novel biomarker-based prognostic score in acute ischemic stroke: The CoRisk score. To derive and externally validate a copeptin-based parsimonious score to predict unfavorable outcome 3 months after an acute ischemic stroke (AIS).The derivation cohort consisted of patients with AIS enrolled prospectively at the University Hospital Basel, Switzerland. The validation cohort was prospectively enrolled after the derivation cohort at the University Hospital of Bern and University Hospital Basel

2019 Neurology

62. Prognostic value of "tissue-based" definitions of TIA and minor stroke: Population-based study. (PubMed)

with TIA or minor stroke (NIH Stroke Scale [NIHSS] ≤3) in the population-based Oxford Vascular Study underwent brain MRI at baseline. Stroke risk on 10-year follow-up was stratified by NIHSS (0/1 vs 2/3) and Trial of Org 10172 in Acute Stroke Treatment classification of the initial event.Among 1,033 patients (633 TIA; 400 minor stroke), 248 (24.0%) had acute lesions on DWI (13.9% of TIAs; 40.0% of minor strokes). A positive DWI was associated with an increased 10-year risk of recurrent ischemic stroke (...) Prognostic value of "tissue-based" definitions of TIA and minor stroke: Population-based study. Since use of diffusion-weighted imaging (DWI) positivity in the "tissue-based" definition of stroke in patients with a clinical TIA is supported by the high associated 90-day risk of recurrent stroke, we aimed to determine long-term prognostic significance, stratified by etiologic subtype, and whether the same tissue-based distinction is predictive in minor strokes.Consecutive eligible patients

Full Text available with Trip Pro

2019 Neurology

63. MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. (PubMed)

MRI-based thrombolytic therapy in patients with acute ischemic stroke presenting with a low NIHSS. Treatment of patients with stroke presenting with minor deficits remains controversial, and the recent Potential of rtPA for Ischemic Strokes with Mild Symptoms (PRISMS) trial, which randomized patients to thrombolysis vs aspirin, did not show benefit. We studied the safety and efficacy of thrombolysis in a population of patients with acute stroke presenting with low NIH Stroke Scale (NIHSS (...) ) scores screened using MRI.The NIH Natural History of Stroke database was reviewed from January 2006 to December 2016 to identify all patients with an initial NIHSS score ≤5 who received thrombolysis within 4.5 hours of symptom onset after being screened with MRI. The 24-hour postthrombolysis MRIs were reviewed for hemorrhagic transformation. Primary outcomes were symptomatic intracranial hemorrhage (sICH) and favorable 90-day outcome modified Rankin Scale score 0-1. Subgroup analysis was performed

2019 Neurology

64. Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke. (PubMed)

Scale score ≥3) at 3 months after ischemic stroke, and secondary outcomes included major disability, death, and vascular events.A total of 843 participants (25.2%) experienced major disability or died within 3 months. After adjustment for age, sex, admission NIH Stroke Scale score, and other important covariates, odds ratios or hazard ratios (95% confidence intervals) of 1-SD (0.17 ng/mL) higher log-TIMP-1 were 1.17 (1.06-1.29) for the primary outcome, 1.13 (1.02-1.25) for major disability, 1.49 (...) Tissue inhibitor metalloproteinase-1 and clinical outcomes after acute ischemic stroke. To prospectively investigate the relationships between serum tissue inhibitor metalloproteinase-1 (TIMP-1) and clinical outcomes in patients with acute ischemic stroke.We derived data from the China Antihypertensive Trial in Acute Ischemic Stroke. Baseline serum TIMP-1 concentrations were measured in 3,342 participants. The primary outcome was the combination of death and major disability (modified Rankin

2019 Neurology

65. Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial. (PubMed)

Disability after minor stroke and TIA: A secondary analysis of the SOCRATES trial. To examine factors associated with disability following TIA and minor stroke, including poststroke complications such as stroke recurrence, major bleeding, and other adverse medical events.The SOCRATES trial randomized patients with TIA/minor stroke (NIH Stroke Scale [NIHSS] score ≤5) within 24 hours of onset. We performed a post hoc analysis of factors associated with disability (modified Rankin Scale [mRS (...) ] score >1). TIA and minor stroke were analyzed separately. Patients with premorbid mRS >0 were excluded.At 90 days, 687/3,663 (19%) patients with stroke were disabled; for TIA, 122/2,384 (5%) were disabled. In multivariate analyses, age, diabetes, and NIHSS were associated with disability in the stroke cohort, and age with disability in the TIA cohort. Postrandomization events (recurrent stroke, myocardial infarction, major bleeding, serious adverse events) were strongly associated with disability

2019 Neurology

66. Outcome of endovascular therapy in stroke with large vessel occlusion and mild symptoms. (PubMed)

Outcome of endovascular therapy in stroke with large vessel occlusion and mild symptoms. To compare outcomes after endovascular therapy (EVT) and IV thrombolysis (IVT) in patients with stroke with emergent large vessel occlusion (LVO) and mild neurologic deficits.This was a retrospective analysis of patients from the Swiss Stroke Registry with admission NIH Stroke Scale score ≤5 and LVO treated by EVT (± IVT) vs IVT alone. The primary endpoint was favorable functional outcome (modified Rankin (...) Scale [mRS] score 0-1) at 3 months. Secondary outcomes were independence (mRS score 0-2), mRS score (ordinal shift analysis), and survival with high disability (mRS score 4-5). Safety endpoints were mortality and symptomatic hemorrhage.Of 11,356 patients, 312 met the criteria and propensity score method matched 108 in each group. A comparably large proportion of patients with EVT and IVT had favorable outcome (63% vs 65.7% respectively; odds ratio 0.94, 95% confidence interval 0.51-1.72; p = 0.840

2019 Neurology

67. Comparative Effectiveness of Pre-stroke Aspirin on Stroke Severity and Outcome. (PubMed)

Comparative Effectiveness of Pre-stroke Aspirin on Stroke Severity and Outcome. The effect of prestroke aspirin use on initial severity, hemorrhagic transformation, and functional outcome of ischemic stroke is uncertain.Using a multicenter stroke registry database, patients with acute ischemic stroke of three subtypes (large artery atherosclerosis [LAA], small vessel occlusion [SVO], or cardioembolism [CE]) were identified. NIH stroke scale (NIHSS) and hemorrhagic transformation at presentation (...) and discharge modified Rankin Scale (mRS) were compared between prestroke aspirin users and nonusers.Among the 10,433 patients, 1,914 (18.3%) reported prestroke aspirin use. On crude analysis, initial NIHSS scores of aspirin users were higher than nonusers (mean difference: 0.35; 95% confidence interval [CI]: 0.04-0.66). However, a multivariable analysis with an application of inverse probability of treatment weighting based on a propensity score of prestroke aspirin, having an interaction effect

Full Text available with Trip Pro

2016 Annals of Neurology

68. Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. (PubMed)

(NIH Stroke Scale score <4).A total of 5,237 TIA and minor stroke patients met inclusion criteria, with 3-month follow-up data available on 2,457. Early and 3-month stroke were observed in 2.4% and 4.2% of the study population. The probability of early stroke during the stroke unit stay (median 2 [interquartile range 1-3] days) steadily increased from 0% to 4.8% and 0% to 16.7% with increasing ABCD2 and ABCD3-I score points, respectively. On 3-month follow-up, stroke risk increased from 0% to 8.0 (...) Predictive value of ABCD2 and ABCD3-I scores in TIA and minor stroke in the stroke unit setting. It is not clear whether risk scores for early stroke recurrence after TIA that have been mainly established in outpatient and emergency department settings are valid on the background of highly specialized stroke unit care.ABCD2 and ABCD3-I scores have been prospectively documented in a cohort of patients admitted to Austrian stroke units within 24 hours of symptom onset with TIA or minor stroke

2016 Neurology

69. Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales

: resources: Groups and Cohorts Go to Outcome Measures Go to Primary Outcome Measures : baseline CSF pressure [ Time Frame: baseline ] CSF pressure at baseline baseline mRS [ Time Frame: baseline ] mRS at baseline baseline papilledema grade [ Time Frame: baseline ] Frisen grade of papilledema at baseline Secondary Outcome Measures : baseline NIHSS [ Time Frame: baseline ] NIH Stroke Scale at baseline Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate (...) Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales Cerebral Venous Sinus Thrombosis: Re-exploration of Clinical Assessment Scales - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more

2017 Clinical Trials

70. Primary Care Corner with Geoffrey Modest MD: The elusive search for afib in stroke patients; and an app

in picking up AF by age, sex, CHADS 2 , NIH Stroke Scale, symptoms at admission, or if the stroke was considered “cryptogenic”)​ Commentary: — The rationale for looking aggressively for atrial fibrillation is that strokes from AF can be more severe, there is a high risk of recurrent strokes, and the detection of AF really changes therapy from antiplatelet drugs to oral anticoagulants, the latter decreasing the risk of recurrent strokes by 60 to 70%. Since there are significant adverse events associated (...) that increase risk of stroke/TIA (and does that number vary depending on the length of AF episodes)? and, is this age-dependent? — at what age should we do more aggressive monitoring (and should there be scaled amounts of monitoring based on different age groups, since AF is more common with increasing age)? is there an age where monitoring stops being clinically useful (either the AF doesn’t really increase risk that much, or the risks start to outweigh the benefits)? the bottom line to me is that if we

2017 Evidence-Based Medicine blog

71. Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians

Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians | Circulation: Cardiovascular Genetics Search Hello Guest! Login to your account Email Password Keep me logged in Search February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump (...) to Free Access article Basic Concepts and Potential Applications of Genetics and Genomics for Cardiovascular and Stroke Clinicians A Scientific Statement From the American Heart Association , MD, PhD, MPH, FAHA, Chair , EdD, ANP, FAHA, Co-Chair , MD, MHS , MD, FAHA , PhD, FAHA , MD, MPH, FAHA , PhD, RN, FAHA , MD , MD, MHS, FAHA , and MD, MS, FAHA MD, MSc, FAHAon behalf of the American Heart Association Council on Functional Genomics and Translational Biology, Council on Clinical Cardiology, Council

Full Text available with Trip Pro

2015 American Heart Association

72. Scientific Rationale for the Inclusion and Exclusion Criteria for Intravenous Alteplase in Acute Ischemic Stroke

Cooperative Acute Stroke Study III; ED, emergency department; INR, international normalized ratio; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; rtPA, recombinant tissue-type plasminogen activator; and SBP, systolic blood pressure. Modified from de Los Rios la Rosa et al. Copyright © 2012, American Heart Association, Inc. However, given the hemorrhage risk associated with alteplase, there are numerous other clinical, radiological, and laboratory (...) Koennecke et al, 2001 Berlin, Germany Single academic center 504 13 32 8 20 40 Azzimondi et al, 1997 Bologna, Italy Single teaching hospital 204 NR 40 12 31 9 7 NIHSS indicates National Institutes of Health Stroke Scale; and NR, not reported. The current exclusion criteria listed in the AHA/ASA 2013 acute stroke management guidelines remain based largely on the criteria listed in the pivotal National Institute of Neurological Disorders and Stroke (NINDS) alteplase trial published in 1996, with a few

Full Text available with Trip Pro

2015 American Heart Association

73. 2015 AHA/ASA Focused Update of the 2013 Guidelines for the Early Management of Patients with Acute Ischemic Stroke Regarding Endovascular Treatment

point of the percentage with good outcome defined as a modified Rankin Scale (mRS) 7,8 score of 0 or 1, death at 3 months, or symptomatic intracerebral hemorrhage (sICH) at 7 days. There were no significant differences in outcomes in subgroups, including time to treatment (0–3 or 3–4.5 hours), baseline National Institutes of Health Stroke Scale (NIHSS) 9 score ( 67 years). 10 The Interventional Management of Stroke Trial III (IMS III) was a PROBE, 2-arm superiority trial that enrolled patients (...) angiography; MRI, magnetic resonance imaging; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; r-tPA, recombinant tissue-type plasminogen activator; REVASCAT, Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours; SWIFT PRIME, Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment of Acute Ischemic Stroke; and UK, urokinase. Downloaded from http://ahajournals.org by on March

2015 Congress of Neurological Surgeons

74. 2015 aha/asa focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment

to treatment (0–3 or 3–4.5 hours), baseline National Institutes of Health Stroke Scale (NIHSS) score (<11 or ≥11), and age (≤67 years or >67 years). Table 2. Selected Eligibility Criteria for Recent Randomized, Clinical Trials of Endovascular Treatments for Acute Ischemic Stroke Treatment Groups Eligibility Study Active vs Control IV r-tPA Eligible Age, y Time Territory NIHSS Score Prestroke Function Anticoagulation/Coagulopathy ASPECTS Vascular Imaging Other Imaging SYNTHESIS Expansion IA drug/any device (...) angiography; MRI, magnetic resonance imaging; mRS, modified Rankin scale; NIHSS, National Institutes of Health Stroke Scale; r-tPA, recombinant tissue-type plasminogen activator; REVASCAT, Endovascular Revascularization With Solitaire Device Versus Best Medical Therapy in Anterior Circulation Stroke Within 8 Hours; SWIFT PRIME, Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment of Acute Ischemic Stroke; and UK, urokinase. Table 3. Selected Patient Characteristics for Recent

2015 American Academy of Neurology

75. Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke

; INR, international normalized ratio; MI, myocardial infarction; NIHSS, National Institutes of Health Stroke Scale; OAC, oral anticoagulant; rtPA, recombinant tissue-type plasminogen activator; and SBP, systolic blood pressure. Modified from de Los Rios la Rosa et al. Copyright © 2012, American Heart Association, Inc. However, given the hemorrhage risk associated with alteplase, there are numerous other clinical, radiological, and laboratory-related exclusion criteria for alteplase (...) 40 Azzimondi et al, 1997 Bologna, Italy Single teaching hospital 204 NR 40 12 31 9 7 NIHSS indicates National Institutes of Health Stroke Scale; and NR, not reported. The current exclusion criteria listed in the AHA/ASA 2013 acute stroke management guidelines remain based largely on the criteria listed in the pivotal National Institute of Neurological Disorders and Stroke (NINDS) alteplase trial published in 1996, with a few modifications over the years. These exclusion criteria were developed

2015 American Academy of Neurology

76. Guidelines for the prevention of stroke in women

Guidelines for the prevention of stroke in women Guidelines for the Prevention of Stroke in Women | Stroke Search Hello Guest! Login to your account Email Password Keep me logged in Search April 2019 March 2019 February 2019 February 2019 January 2019 Free Access article Share on Jump to Free Access article Guidelines for the Prevention of Stroke in Women A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , MD, MHS, FAHA , MD, PhD, FAHA , MD (...) , MSc , MD, MPH, FAHA , DNP, RN, FAHA , MD, MPH, FAHA , PhD, MSPH, FAHA , PhD, MPH , PhD, MPH, FAHA , MD, MPH, FAHA , PhD, DVM, FAHA , MD, MPH , MD, MSc, FAHA , MD, FAHA , MD , and MD, PhD MD, MBChB, MScon behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Epidemiology and Prevention, and Council for High Blood Pressure Research Cheryl Bushnell , Louise D. McCullough , Issam A. Awad , Monique V. Chireau

Full Text available with Trip Pro

2014 American Academy of Neurology

77. Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States

Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses cookies. By continuing to browse (...) this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Status of Cardiovascular Disease and Stroke in Hispanics/Latinos in the United States A Science Advisory From the American Heart Association , MD, MPH, FAHA , MD, MPH, FAHA , MD, PhD, FAHA , MD, PhD, FAHA , PhD, FAHA , MD, MS, FAHA , MD, MS, FAHA , MD, MPH, FAHA , PhD, MPH , and PhD, MPH PhD, MS, FAHAon behalf of the American Heart Association Council on Epidemiology and Prevention, Council

Full Text available with Trip Pro

2014 American Heart Association

78. Guidelines for the Prevention of Stroke in Women

Guidelines for the Prevention of Stroke in Women 1545 Purpose—The aim of this statement is to summarize data on stroke risk factors that are unique to and more common in women than men and to expand on the data provided in prior stroke guidelines and cardiovascular prevention guidelines for women. This guideline focuses on the risk factors unique to women, such as reproductive factors, and those that are more common in women, including migraine with aura, obesity, metabolic syndrome, and atrial (...) fibrillation. Methods—Writing group members were nominated by the committee chair on the basis of their previous work in relevant topic areas and were approved by the American Heart Association (AHA) Stroke Council’s Scientific Statement Oversight Committee and the AHA’s Manuscript Oversight Committee. The panel reviewed relevant articles on adults using computerized searches of the medical literature through May 15, 2013. The evidence is organized within the context of the AHA framework and is classified

2014 Congress of Neurological Surgeons

79. Heart Disease and Stroke Statistics?2016 Update

Heart Disease and Stroke Statistics?2016 Update Heart Disease and Stroke Statistics—2016 Update | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search October 2019 September 2019 August 2019 July 2019 June 2019 May 2019 April 2019 March 2019 February 2019 January 2019 This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies. Free Access article Share on Jump to Free Access article Heart Disease and Stroke (...) , MD, MSCR, FAHA , MD, PhD , MD, MS, FAHA , and MD, MSc, FAHA MPHon behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Dariush Mozaffarian , Emelia J. Benjamin , Alan S. Go , Donna K. Arnett , Michael J. Blaha , Mary Cushman , Sandeep R. Das , Sarah de Ferranti , Jean-Pierre Després , Heather J. Fullerton , Virginia J. Howard , Mark D. Huffman , Carmen R. Isasi , Monik C. Jiménez , Suzanne E. Judd , Brett M. Kissela , Judith H. Lichtman , Lynda D

2014 American Heart Association

80. Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial. (PubMed)

after the onset of stroke. The patients were treated with Cerebrolysin (30 mL over seven days followed by 10 mL until day 30) or placebo once daily over a period of four weeks. Efficacy was primarily assessed by the NIH Stroke Scale at day 30, and additional parameters included the modified Rankin Scale, the Clinical Global Impression, the Patient Global Satisfaction (PGS) and the Mini Mental State Examination (MMSE). Nonparametric statistical procedures employing the Wilcoxon-Mann-Whitney test were (...) used for data analysis. Safety and tolerability were assessed by adverse events, vital signs, and laboratory parameters. Results.The estimated effect size on the change from baseline in the NIH Stroke Scale on day 30 indicated a medium to large superiority of cerebrolysin compared to placebo (Mann-Whitney [MW] 0.66; 95% confidence interval [CI] 0.55-0.78, P=0.005). Similar effect sizes were reported for the modified Ranking Scale (MW 0.65; 95% CI 0.54-0.76; P=0.010) and the Clinical Global

2018 Journal of medicine and life

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>